尿路上皮癌
化疗
医学
肿瘤科
内科学
癌症
膀胱癌
泌尿科
出处
期刊：Cancer Discovery
[American Association for Cancer Research]
日期：2021-03-04
卷期号：11 (5): OF8-OF8
标识
DOI：10.1158/2159-8290.cd-nb2021-0321
摘要
Enfortumab vedotin recently demonstrated greater efficacy than standard chemotherapy in patients with previously treated advanced urothelial cancer: In a phase III trial, the agent led to a median overall survival of 12.9 months, compared with 9 months in patients who received chemotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI
MchemG
YifanWang
pluto
VDC
ceeray23
斯寜
剑指东方是为谁
Xiaoxiao
迷人秋烟
Magali
cctv18
123
morena
小李老博
核桃
昏睡的蟠桃
Marciu33
nenoaowu
HEIKU
tutuMandy
皖公网安备34019202002308
